Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 7/20 | 0.50 |
| ▸ | DRD3 | P35462 | 7/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987427 | 0.96 | DRD2 (0.53) | DRD2ACEDRD4DRD3SIRT5 | |
| SCHEMBL30987423 | 0.89 | DRD2 (0.52) | DRD2ACEDRD4DRD3SIRT5 | |
| SCHEMBL5094706 | 0.82 | GRIN1 (0.60) | DRD2ACEGRIN1GRIN2B | |
| SCHEMBL2838230 | 0.81 | DRD2 (0.59) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL2409690 | 0.81 | DRD2 (0.49) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL15189254 | 0.81 | DRD2 (0.53) | DRD2ACEDRD3 | |
| SCHEMBL13980490 | 0.80 | SLC6A4 (0.57) | DRD2ACEDRD4DRD3SIRT5 | |
| SCHEMBL2413737 | 0.80 | DRD2 (0.51) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL18688683 | 0.80 | DRD2 (0.58) | DRD2ACEDRD4DRD3CHRM2 | |
| SCHEMBL30987424 | 0.79 | DRD2 (0.50) | DRD2ACECHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838696-B1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2016-03-09 | — | — | EP | disclosed |
| US-8053446-B2 | Cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2011-11-08 | — | — | US | disclosed |
| US-20080312275-A1 | Novel Cyanoguanidine Compounds | LEO PHARMA A/S (DK) | 2008-12-18 | — | — | US | disclosed |
| EP-1838696-A1 | NOVEL CYANOGUANIDINE COMPOUNDS | Leo Pharma A/S (DK) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006066584-A1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA A/S (DK) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312275-A1 | Novel Cyanoguanidine Compounds | MKI67, CCNA1, COL1A1 | DRD2 2257/4885ACE 2462/4885DRD4 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.